Relationship between age and erectile dysfunction diagnosis or treatment using real-world observational data in the USA
Authors:
- 29 December 2016
- journal article
- research article
- Published by Wiley in International Journal Of Clinical Practice
- Vol. 70 (12) , 1012-1018
Abstract
Aims With self‐reporting of erectile dysfunction (ED) in population‐based surveys, men with ED may not represent men who are bothered sufficiently to seek an ED diagnosis and treatment. We used real‐world observational data to assess: 1) the prevalence of ED diagnosis or treatment by age subgroups; and 2) the relationship of age with ED diagnosis or treatment after controlling for ED‐related comorbidities in the USA. Methods This cross‐sectional study used de‐identified claims data (MarketScan® databases; primary analysis). Sensitivity analysis was conducted using electronic health records (Humedica® database). Inclusion criteria were men aged ≥18 years with a 360‐day continuous enrollment before the index date. We assessed the prevalence of ED diagnosis or phosphodiesterase type 5 inhibitor (PDE5I) prescription by age and the risk for ED diagnosis or treatment by age after controlling for comorbidities (hypertension, other cardiovascular disease, diabetes mellitus, depression and benign prostatic hyperplasia). Results Of 19,833,939 men meeting inclusion criteria in the primary analysis, only 1 108 842 (5.6%) had an ED diagnosis or PDE5I prescription (mean [SD] age: 55.2 [11.2] years). Prevalence of ED diagnosis or treatment increased from age 18–29 years (0.4%) to 60–69 years (11.5%), then decreased in the seventh (11.0%), eighth (4.6%), and ninth (0.9%) decades. Men with ED diagnosis or treatment had a higher prevalence of any comorbidity (63.1% vs 29.3% for men without ED) and of each comorbid condition. In multivariate analyses, age was an independent risk factor for ED diagnosis or treatment. Sensitivity analysis provided consistent results. Conclusions In a real‐world setting in the USA, the prevalence of ED diagnosis or PDE5I treatment is generally low, increases with age, decreases in very old men, and is associated with increased prevalence of comorbidities. Age is an independent risk factor for ED diagnosis or treatment after controlling for comorbidities.Keywords
Funding Information
- Pfizer
This publication has 31 references indexed in Scilit:
- Risk assessment of readmissions following an initial COPD-related hospitalizationInternational Journal of Chronic Obstructive Pulmonary Disease, 2013
- Official statistics and claims data records indicate non-response and recall bias within survey-based estimates of health care utilization in the older populationBMC Health Services Research, 2013
- Relative contributions of modifiable risk factors to erectile dysfunction: Results from the Boston Area Community Health (BACH) SurveyPreventive Medicine, 2010
- Erectile Dysfunction and MortalityThe Journal of Sexual Medicine, 2009
- Association between Smoking, Passive Smoking, and Erectile Dysfunction: Results from the Boston Area Community Health (BACH) SurveyEuropean Urology, 2007
- Prevalence of storage and voiding symptoms among men aged 40 years and older in a US population-based study: results from the Male Attitudes Regarding Sexual Health studyInternational Journal Of Clinical Practice, 2007
- Erectile Dysfunction—An Observable Marker of Diabetes Mellitus? A Large National Epidemiological StudyJournal of Urology, 2006
- HEALTH ISSUES OF MEN: PREVALENCE AND CORRELATES OF ERECTILE DYSFUNCTIONJournal of Urology, 2005
- ARE MEN WITH ERECTILE DYSFUNCTION MORE LIKELY TO HAVE HYPERTENSION THAN MEN WITHOUT ERECTILE DYSFUNCTION? A NATURALISTIC NATIONAL COHORT STUDYJournal of Urology, 2005
- Prevalence and Risk Factors for Erectile Dysfunction in 2869 Men Using a Validated QuestionnaireEuropean Urology, 2005